About: Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis
Creator	Chen, Dechang Sun, Renhua Jin, Yiyang Li, Ranran Yang, Xianghong Zhang, Zhongheng
Source	Medline; PMC
abstract	BACKGROUND: The aim of this study is to assess the prevalence of abnormal urine analysis and kidney dysfunction in COVID-19 patients and to determine the association of acute kidney injury (AKI) with the severity and prognosis of COVID-19 patients. METHODS: The electronic database of Embase and PubMed were searched for relevant studies. A meta-analysis of eligible studies that reported the prevalence of abnormal urine analysis and kidney dysfunction in COVID-19 was performed. The incidences of AKI were compared between severe versus non-severe patients and survivors versus non-survivors. RESULTS: A total of 24 studies involving 4963 confirmed COVID-19 patients were included. The proportions of patients with elevation of sCr and BUN levels were 9.6% (95% CI 5.7–13.5%) and 13.7% (95% CI 5.5–21.9%), respectively. Of all patients, 57.2% (95% CI 40.6–73.8%) had proteinuria, 38.8% (95% CI 26.3–51.3%) had proteinuria +, and 10.6% (95% CI 7.9–13.3%) had proteinuria ++ or +++. The overall incidence of AKI in all COVID-19 patients was 4.5% (95% CI 3.0–6.0%), while the incidence of AKI was 1.3% (95% CI 0.2–2.4%), 2.8% (95% CI 1.4–4.2%), and 36.4% (95% CI 14.6–58.3%) in mild or moderate cases, severe cases, and critical cases, respectively. Meanwhile, the incidence of AKI was 52.9%(95% CI 34.5–71.4%), 0.7% (95% CI − 0.3–1.8%) in non-survivors and survivors, respectively. Continuous renal replacement therapy (CRRT) was required in 5.6% (95% CI 2.6–8.6%) severe patients, 0.1% (95% CI − 0.1–0.2%) non-severe patients and 15.6% (95% CI 10.8–20.5%) non-survivors and 0.4% (95% CI − 0.2–1.0%) survivors, respectively. CONCLUSION: The incidence of abnormal urine analysis and kidney dysfunction in COVID-19 was high and AKI is closely associated with the severity and prognosis of COVID-19 patients. Therefore, it is important to increase awareness of kidney dysfunction in COVID-19 patients.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1186/s13054-020-03065-4
bibo:pmid	32552872
has license	cc-by
sha1sum (hex)	4d822c9ed0412ddaa87d8521ba2b58925ba70803
schema:url	https://doi.org/10.1186/s13054-020-03065-4
resource representing a document's title	Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis
has PubMed Central identifier	PMC7300374
has PubMed identifier	32552872
schema:publication	Crit Care
resource representing a document's body	covid:4d822c9ed0412ddaa87d8521ba2b58925ba70803#body_text
is schema:about of	named entity '95% CI' named entity 'COVID-19' named entity 'COVID-19' named entity 'incidence' named entity 'abnormal' named entity 'Methods' named entity 'survivors' named entity '95% CI' named entity 'The' named entity 'The' named entity 'patients' named entity 'COVID-19' named entity 'kidney' named entity 'studies' named entity 'patients' named entity 'The' named entity 'prevalence' named entity 'levels' named entity '95% CI' named entity 'PubMed' named entity 'COVID-19' named entity 'renal impairment' named entity '95% CI' named entity '95% CI' named entity '95% CI' named entity 'relative risk' named entity 'COVID-19' named entity 'ARDS' named entity 'clinical practice' named entity 'ischemia' named entity 'random effect' named entity '95% CI' named entity 'COVID-19' named entity 'Embase' named entity 'COVID-19' named entity 'proteinuria' named entity 'COVID-19' named entity 'meta-analysis' named entity 'CRRT' named entity 'ICU' named entity '5.7' named entity 'Forest plot' named entity 'random effect' named entity 'kidney' named entity '3.6.3' named entity 'renal impairment' named entity '5.5' named entity 'forest plot' named entity 'risk factor' named entity 'China' named entity '95% CI' named entity 'proteinuria' named entity 'Meta-analyses' named entity 'BUN' named entity 'Heterogeneity' named entity 'Heterogeneity' named entity '0.01' named entity 'CRRT' named entity 'COVID-19' named entity 'serum creatinine' named entity 'proteinuria' named entity 'meta-analysis' named entity 'CRRT' named entity 'BUN' named entity 'symptom' named entity 'BUN' named entity 'Guangzhou' named entity 'COVID-19' named entity 'meta-analysis' named entity 'proteinuria' named entity 'Heterogeneity' named entity '7.9' named entity 'CRRT' named entity 'blood flow' named entity '0.01' named entity 'proteinuria'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software